Edition:
United States

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

2.62USD
13 Jan 2017
Change (% chg)

$0.05 (+1.95%)
Prev Close
$2.57
Open
$2.59
Day's High
$2.73
Day's Low
$2.55
Volume
26,370
Avg. Vol
17,609
52-wk High
$6.12
52-wk Low
$1.66

IMMY.OQ

Chart for IMMY.OQ

About

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $33.93
Shares Outstanding(Mil.): 13.25
Dividend: --
Yield (%): --

Financials

  IMMY.OQ Industry Sector
P/E (TTM): -- 46.47 30.92
EPS (TTM): -1.59 -- --
ROI: -134.06 -0.87 14.82
ROE: -713.51 -0.56 16.24

BRIEF-Imprimis Pharmaceuticals reports Q3 loss per share $0.29

* Imprimis Pharmaceuticals announces third quarter 2016 financial results Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-Imprimis Pharmaceuticals signs agreement with specialty pharmacy division of one of the nation's largest pharmacy benefit managers

* Imprimis Pharmaceuticals signs agreement with specialty pharmacy division of one of the nation's largest pharmacy benefit managers

Nov 10 2016

BRIEF-Imprimis Pharma says registers its New Jersey facility with the FDA

* Imprimis pharmaceuticals registers its new jersey facility with the fda as an outsourcing facility

Oct 28 2016

BRIEF-Imprimis' Dropless Therapy shows advantages in peer-reviewed study

* Imprimis' Dropless Therapy shows significant advantages in a large peer-reviewed study Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Oct 25 2016

BRIEF-Imprimis reports availability of lower-cost option for the treatment of lead poisoning

* Imprimis Pharmaceuticals announces availability of lower-cost option for the treatment of lead poisoning

Oct 17 2016

BRIEF-Imprimis Pharmaceuticals implemented an expense reduction program

* Has ceased operations at its Texas facility and implemented an 8% reduction in total headcount

Sep 26 2016

BRIEF-Imprimis Pharmaceuticals Q2 revenue $4.9 million

* Imprimis pharmaceuticals announces second quarter 2016 financial results

Aug 15 2016

BRIEF-Imprimis Pharmaceuticals $2 mln sale agreement with Essex Capital

* Agreement covers sale and leaseback of Imprimis' drug manufacturing equipment and has an initial term of up to three years

Aug 11 2016

Competitors

  Price Chg
Eli Lilly and Co (LLY.N) $77.40 +0.25
Sanofi SA (SASY.PA) €77.38 -0.69
Bayer AG (BAYGn.DE) €101.00 -0.65
Bayer AG (BAYE.F) -- --
Roche Holding Ltd. (ROG.S) CHF236.40 -2.60
Roche Holding Ltd. (RO.S) CHF240.80 -2.60
Merck & Co., Inc. (MRK.N) $62.34 +0.13
Novartis AG (NOVN.S) CHF72.25 -0.75

Earnings vs. Estimates